Jinglin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinglin Wang has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Kaiping Wang
Hubei Key Laboratory of Natural Active Polysaccharides, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, 430022, China; Tongji Medical College of Pharmacy, Huazhong University of Science and Technology, 430030, Wuhan, China
10 shared publications - Yu Zhang
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China; Hubei Key Laboratory of Natural Active Polysaccharides, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, 430022, China
10 shared publications Yan Liu
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China; Hubei Key Laboratory of Natural Active Polysaccharides, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, 430022, China
6 shared publicationsYu Zhang
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, China; Hubei province clinical research center for precision medicine for critical illness, 430030 Wuhan, China
4 shared publicationsJingyi Wang
Tongji Medical College of Pharmacy, Huazhong University of Science and Technology, 430030, Wuhan, PR China
3 shared publicationsJunxi Liu
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China; Hubei Key Laboratory of Natural Active Polysaccharides, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, 430022, China
3 shared publications
Latest Publications
- 23 April 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 364, 152182
Angelica sinensis polysaccharides modulate iron metabolism and macrophage polarization to alleviate rheumatoid arthritis
- 23 April 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 364, 152182
Angelica sinensis polysaccharides modulate iron metabolism and macrophage polarization to alleviate rheumatoid arthritis
- 11 March 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 354, 151391
Lentinan inhibits breast cancer cell growth through the dual downregulation of tumor-promoting effectors CD133 and SCGB2A2
- 11 March 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 354, 151391
Lentinan inhibits breast cancer cell growth through the dual downregulation of tumor-promoting effectors CD133 and SCGB2A2
- 4 February 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 347, 150597
Mechanistic insights into the hepatic metabolism of lentinan: A TLR2–ROS–lysosome axis
- 4 February 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 347, 150597
Mechanistic insights into the hepatic metabolism of lentinan: A TLR2–ROS–lysosome axis
- Open Access
- 10 December 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1725716
Lentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133/p85/p-AKT signaling axis
Background: Colorectal cancer (CRC) ranks third in the global cancer incidence rate worldwide. Cancer stem cells (CSCs) are key drivers of CRC recurrence, metastasis, and therapy resistance, while therapies against them remain limited. Lentinan is widely recognized for its strong immune-enhancing and broad-spectrum directly antitumor activities, however, whether it has potential for cancer stemness remains unknown. Methods: The CRC cell lines HCT116 and SW620 were selected for pharmacodynamic investigation. Furthermore, tumor sphere formation and limiting dilution assays were used to assess the impact of SLNT on stemness of CRC. Using cell sorting alongside cluster of differentiation 133 (CD133) knockdown and overexpression experiments, the key molecular targets of SLNT in exerting anti-CRC effects were identified. To further elucidate the underlying molecular mechanism, we performed localized surface plasmon resonance (LSPR), cellular thermal shift assay (CETSA), and molecular docking simulations. Additionally, western blot analysis was conducted to validate the key signaling molecules involved. Results: Our results demonstrated that lentinan significantly suppressed the proliferation and stemness of CRC cell lines HCT116 and SW620. We identified CD133 as a critical functional target and confirmed a direct binding interaction between lentinan and CD133. Finally, we revealed that lentinan suppresses stemness by inhibiting the CD133/ phosphatidylinositol 3-kinase 85 kDa regulatory subunit (p85)/ phosphorylated AKT serine/threonine kinase (p-AKT) signaling axis in CRC. Conclusion: Our findings not only shed new light on the anti-tumor mechanism of lentinan, highlighting the scientific potential of natural polysaccharides in cancer treatment, but also offers new options for the clinical drug therapy of CRC.
- 10 December 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1725716
Open AccessLentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133/p85/p-AKT signaling axis
Background: Colorectal cancer (CRC) ranks third in the global cancer incidence rate worldwide. Cancer stem cells (CSCs) are key drivers of CRC recurrence, metastasis, and therapy resistance, while therapies against them remain limited. Lentinan is widely recognized for its strong immune-enhancing and broad-spectrum directly antitumor activities, however, whether it has potential for cancer stemness remains unknown. Methods: The CRC cell lines HCT116 and SW620 were selected for pharmacodynamic investigation. Furthermore, tumor sphere formation and limiting dilution assays were used to assess the impact of SLNT on stemness of CRC. Using cell sorting alongside cluster of differentiation 133 (CD133) knockdown and overexpression experiments, the key molecular targets of SLNT in exerting anti-CRC effects were identified. To further elucidate the underlying molecular mechanism, we performed localized surface plasmon resonance (LSPR), cellular thermal shift assay (CETSA), and molecular docking simulations. Additionally, western blot analysis was conducted to validate the key signaling molecules involved. Results: Our results demonstrated that lentinan significantly suppressed the proliferation and stemness of CRC cell lines HCT116 and SW620. We identified CD133 as a critical functional target and confirmed a direct binding interaction between lentinan and CD133. Finally, we revealed that lentinan suppresses stemness by inhibiting the CD133/ phosphatidylinositol 3-kinase 85 kDa regulatory subunit (p85)/ phosphorylated AKT serine/threonine kinase (p-AKT) signaling axis in CRC. Conclusion: Our findings not only shed new light on the anti-tumor mechanism of lentinan, highlighting the scientific potential of natural polysaccharides in cancer treatment, but also offers new options for the clinical drug therapy of CRC.
- Open Access
Mucormycosis in Paediatric Patients After Haematopoietic Stem Cell Transplantation: A Systematic Review and Meta‐Analysis
Background: Data on the epidemiology, diagnostic methods and evidence‐based recommended treatment methods for children with mucormycosis who have undergone Haematopoietic stem cell transplantation (HSCT) are limited. Objective: Summarise past recommendations and the latest literature on the treatment of HSCT in children with mucorin infection and clarify the epidemiology, diagnosis, treatment and outcomes of this invasive fungal disease. Methods: A comprehensive search for full‐text studies involving humans that were published in English between January 2000 and December 2022 was conducted in Ovid MEDLINE and Ovid Embase using various key words and MeSH terms. Results: A total of 951 articles were identified in the initial database search, of which 28 (32 individual patients) were included in the final analysis. The majority of HSCT recipients (14/26, 54%) had a diagnosis of mucormycosis within 30 days posttransplant, with a median time from transplant to diagnosis of 19 (27 patients; IQR, 13–213) days. Pulmonary mucormycosis (9/32, 28%) and disseminated mucormycosis (9/32, 28%) were the most commonly observed manifestations in paediatric patients after HSCT. Targeted antifungal therapy was used in 27 patients. Iv AmB formulations were the most commonly administered first‐line treatment (26/27, 96%). Compared with iv AmB monotherapy, initial treatment with combination antifungal therapy appeared to improve all‐cause mortality [3/10 (30%) vs. 6/17 (35%)]. Conclusions: The results of the present review will help to determine the pathology, diagnosis, treatment and outcomes of this invasive fungal disease.
Open AccessMucormycosis in Paediatric Patients After Haematopoietic Stem Cell Transplantation: A Systematic Review and Meta‐Analysis
Background: Data on the epidemiology, diagnostic methods and evidence‐based recommended treatment methods for children with mucormycosis who have undergone Haematopoietic stem cell transplantation (HSCT) are limited. Objective: Summarise past recommendations and the latest literature on the treatment of HSCT in children with mucorin infection and clarify the epidemiology, diagnosis, treatment and outcomes of this invasive fungal disease. Methods: A comprehensive search for full‐text studies involving humans that were published in English between January 2000 and December 2022 was conducted in Ovid MEDLINE and Ovid Embase using various key words and MeSH terms. Results: A total of 951 articles were identified in the initial database search, of which 28 (32 individual patients) were included in the final analysis. The majority of HSCT recipients (14/26, 54%) had a diagnosis of mucormycosis within 30 days posttransplant, with a median time from transplant to diagnosis of 19 (27 patients; IQR, 13–213) days. Pulmonary mucormycosis (9/32, 28%) and disseminated mucormycosis (9/32, 28%) were the most commonly observed manifestations in paediatric patients after HSCT. Targeted antifungal therapy was used in 27 patients. Iv AmB formulations were the most commonly administered first‐line treatment (26/27, 96%). Compared with iv AmB monotherapy, initial treatment with combination antifungal therapy appeared to improve all‐cause mortality [3/10 (30%) vs. 6/17 (35%)]. Conclusions: The results of the present review will help to determine the pathology, diagnosis, treatment and outcomes of this invasive fungal disease.
- 5 March 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 307 (Pt 1) , 141784
Lentinan mitigates ulcerative colitis via the IL-22 pathway to repair the compromised mucosal barrier and enhance antimicrobial defense
- 5 March 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 307 (Pt 1) , 141784
Lentinan mitigates ulcerative colitis via the IL-22 pathway to repair the compromised mucosal barrier and enhance antimicrobial defense
- Open Access
- 17 February 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1) , 2464781
Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial
The addition of cadonilimab to first-line platinum-based chemotherapy with or without bevacizumab significantly improved progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer. However, the economic value of using this novel therapy for this indication is currently unknown. The aim of this study is to evaluate the cost-effectiveness of the addition of cadonilimab to first-line standard chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer from the perspective of Chinese healthcare system. A partitioned survival model was constructed to compare the cost-effectiveness of cadonilimab versus placebo in patients enrolled in the COMPASSION-16 trial. Cost, life-year, quality-adjusted life-year (QALY), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB) were calculated for 2 treatment strategies. Sensitivity, scenario, and subgroup analyses, and value of information analysis (EVPI) were performed. Cadonilimab provided an additional 1.18 QALYs and $89,528.64 compared with placebo, which resulted in an ICER of $75,944.56/QALY. At the willingness-to-pay threshold of $38,042.49/QALY, INHB was estimated to be −1.17 QALYs, while INMB amounted to −$44,681.55 and EVPI was calculated as $71.40/person. Sensitivity analyses revealed that the model was most sensitive to hazard ratio (HR) for OS and PFS, and the probability of cadonilimab being cost-effective was 0.70%. To achieve cost-effectiveness, the price of cadonilimab must be reduced by approximately 50%. Subgroup analysis found that all subgroups unfavored cadonilimab by varying the HR for OS and PFS. Scenario analyses showed using life-year as effectiveness, altering time horizon and selection of survival analysis did not reverse results. Although the use of cadonilimab resulted in clinical benefit, it was not deemed cost-effective as a first-line therapy for persistent, recurrent, or metastatic cervical cancer in China. Lowering the price of cadonilimab may enhance its cost-effectiveness.
- 17 February 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1) , 2464781
Open AccessCost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial
The addition of cadonilimab to first-line platinum-based chemotherapy with or without bevacizumab significantly improved progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer. However, the economic value of using this novel therapy for this indication is currently unknown. The aim of this study is to evaluate the cost-effectiveness of the addition of cadonilimab to first-line standard chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer from the perspective of Chinese healthcare system. A partitioned survival model was constructed to compare the cost-effectiveness of cadonilimab versus placebo in patients enrolled in the COMPASSION-16 trial. Cost, life-year, quality-adjusted life-year (QALY), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB) were calculated for 2 treatment strategies. Sensitivity, scenario, and subgroup analyses, and value of information analysis (EVPI) were performed. Cadonilimab provided an additional 1.18 QALYs and $89,528.64 compared with placebo, which resulted in an ICER of $75,944.56/QALY. At the willingness-to-pay threshold of $38,042.49/QALY, INHB was estimated to be −1.17 QALYs, while INMB amounted to −$44,681.55 and EVPI was calculated as $71.40/person. Sensitivity analyses revealed that the model was most sensitive to hazard ratio (HR) for OS and PFS, and the probability of cadonilimab being cost-effective was 0.70%. To achieve cost-effectiveness, the price of cadonilimab must be reduced by approximately 50%. Subgroup analysis found that all subgroups unfavored cadonilimab by varying the HR for OS and PFS. Scenario analyses showed using life-year as effectiveness, altering time horizon and selection of survival analysis did not reverse results. Although the use of cadonilimab resulted in clinical benefit, it was not deemed cost-effective as a first-line therapy for persistent, recurrent, or metastatic cervical cancer in China. Lowering the price of cadonilimab may enhance its cost-effectiveness.
- Top Cited Papers
- 3 October 2024
- Published by Elsevier in Carbohydrate Polymers
- Vol. 349 (Pt A) , 122829
Astragalus polysaccharides alleviate DSS-induced ulcerative colitis in mice by restoring SCFA production and regulating Th17/Treg cell homeostasis in a microbiota-dependent manner
- 3 October 2024
- Published by Elsevier in Carbohydrate Polymers
- Vol. 349 (Pt A) , 122829
Top Cited PapersAstragalus polysaccharides alleviate DSS-induced ulcerative colitis in mice by restoring SCFA production and regulating Th17/Treg cell homeostasis in a microbiota-dependent manner
- 8 August 2024
- Published by Elsevier in Carbohydrate Polymers
- Vol. 346, 122586
Insights into oral lentinan immunomodulation: Dectin-1-mediated lymphatic transport from Peyer's patch M cells to mononuclear phagocytes
- 8 August 2024
- Published by Elsevier in Carbohydrate Polymers
- Vol. 346, 122586
Insights into oral lentinan immunomodulation: Dectin-1-mediated lymphatic transport from Peyer's patch M cells to mononuclear phagocytes